EpiVax continues to “meet” with global clients despite pandemic restrictions through virtual meetings and conferences such as TIDES: Oligonucleotide and Peptide Therapeutics Virtual!
In addition to participating in a Live Panel Discussion on FDA Draft Guidance on ANDA Filings for Peptides, our CEO/CSO Dr. Annie De Groot contributed a recorded session: New Dogs/Old Tricks: Methods for Assessing the Immunogenicity of Peptide Drugs and Their Impurities, a Case Study of Salmon Calcitonin and Teriparatide
You may watch Dr. De Groot’s pre-recorded talk here:
Read more about EpiVax’s PANDA Strategy.
Also participating at the conference was Aimee Mattei from our Immunoinformatics Department. She presented a poster with recording:
Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications
You may view the poster here.
Would you like more information about PANDA? Join us on Wednesday October 7, 2020 at 11:00AM EDT for a live webinar with Q&A!
